Catalyst Financial Partners LLC Sells 1,621 Shares of Bristol-Myers Squibb (NYSE:BMY)

Catalyst Financial Partners LLC reduced its stake in Bristol-Myers Squibb (NYSE:BMY) by 24.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 4,960 shares of the biopharmaceutical company’s stock after selling 1,621 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Bristol-Myers Squibb were worth $206,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. IMA Advisory Services Inc. bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at approximately $219,000. Raymond James Trust N.A. grew its position in Bristol-Myers Squibb by 3.2% during the 2nd quarter. Raymond James Trust N.A. now owns 111,723 shares of the biopharmaceutical company’s stock worth $4,640,000 after acquiring an additional 3,500 shares during the last quarter. Wedgewood Investors Inc. PA bought a new stake in Bristol-Myers Squibb during the 2nd quarter worth approximately $230,000. Northcape Wealth Management LLC grew its position in Bristol-Myers Squibb by 3.9% during the 2nd quarter. Northcape Wealth Management LLC now owns 6,726 shares of the biopharmaceutical company’s stock worth $279,000 after acquiring an additional 254 shares during the last quarter. Finally, AMG National Trust Bank grew its position in Bristol-Myers Squibb by 166.1% during the 2nd quarter. AMG National Trust Bank now owns 117,595 shares of the biopharmaceutical company’s stock worth $4,884,000 after acquiring an additional 73,403 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on BMY. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft reduced their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. TD Cowen upped their price objective on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a report on Monday, August 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $45.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, July 22nd. Finally, Barclays upped their price objective on Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $54.93.

Bristol-Myers Squibb Trading Up 0.5 %

Shares of BMY traded up $0.23 during trading hours on Monday, reaching $48.34. The stock had a trading volume of 3,203,823 shares, compared to its average volume of 15,608,799. The company has a quick ratio of 0.99, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.41. The firm has a 50-day moving average of $44.38 and a 200 day moving average of $46.56. The company has a market cap of $97.99 billion, a P/E ratio of -15.62, a P/E/G ratio of 12.51 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. The business had revenue of $12.20 billion during the quarter, compared to analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.75 EPS. On average, sell-side analysts expect that Bristol-Myers Squibb will post 0.77 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.96%. The ex-dividend date of this dividend was Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.